

Global Nasal Spray Market - Industry Trends and Forecast to 2030

Market Report | 2023-03-01 | 261 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$4800.00
- Corporate Users License \$7000.00

Report description:

The global nasal spray market is projected to register a CAGR of 6.7% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Global Nasal Spray Market, By Product Type (Decongestion Nasal Spray, Steroid Nasal Spray, Salt Water Solution/Saline Nasal Spray, and Others), Container Design (Pump Bottles and Pressurized Canisters), Dosage Form (Multi Dose, Unit/Single Dose, and Bi Dose), Therapeutic Class (Antihistamine, Nasal Steroid, Mast Cell Inhibitor, and Anticholinergic), Application (Nasal Congestion, Allergic and Non-Allergic Rhinitis, Central Nervous System Disorders, Vaccination, and Others), Prescription/Availability (Over The Counter and Prescribed), End User (Home Care Settings, Hospitals, Clinics, and Community Health Care), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Malaysia, Thailand, Singapore, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the global nasal spray market are:

- Rise in the therapeutic application of the nasal spray
- Increase in the demand for nasal sprays for allergic diseases and pandemics such as COVID-19

Market Players

Some of the major market players operating in the global nasal spray market are:

- EMERGENT
- Cipla Inc.
- Sandoz International GmbH (A Part of Novartis)
- Aytu Health (A subsidiary of Aytu BioPharma, Inc.)
- Bayer AG
- GlaxoSmithKline plc.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

- Assertio Therapeutics, Inc.
- Aurena Laboratories.
- J Pharmaceuticals
- St. Renatus.
- Ultratech India Limited
- Catalent, Inc.
- Teva Pharmaceuticals USA, Inc. (A subsidiary of Teva Pharmaceutical Industries Ltd)
- Pfizer Inc.
- Viatris Inc.
- LEEFORD HEALTHCARE LTD
- Aishwarya Group

Table of Contents:

TABLE OF CONTENTS	
1 INTRODUCTION	23
1.1 OBJECTIVES OF THE STUDY	23
1.2 MARKET DEFINITION	23
1.3 OVERVIEW	23
1.4 LIMITATIONS	25
1.5 MARKETS COVERED	25
2 MARKET SEGMENTATION	27
2.1 MARKETS COVERED	27
2.2 GEOGRAPHICAL SCOPE	28
2.3 YEARS CONSIDERED FOR THE STUDY	29
2.4 CURRENCY AND PRICING	29
2.5 DBMR TRIPOD DATA VALIDATION MODEL	30
2.6 MULTIVARIATE MODELLING	33
2.7 PRODUCT TYPE LIFELINE CURVE	33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	34
2.9 DBMR MARKET POSITION GRID	35
2.10 MARKET END USER COVERAGE GRID	36
2.11 VENDOR SHARE ANALYSIS	37
2.12 SECONDARY SOURCES	38
2.13 ASSUMPTIONS	38
3 EXECUTIVE SUMMARY	39
4 PREMIUM INSIGHTS	42
4.1 PORTER'S FIVE FORCES MODEL	45
4.2 PESTEL ANALYSIS	46
5 INDUSTRY INSIGHTS: GLOBAL NASAL SPRAY MARKET	47
5.1 INDUSTRY INSIGHTS	47
6 REGULATIONS: GLOBAL NASAL SPRAY MARKET	48
6.1 REGULATORY SCENARIO IN THE U.S.	48
6.2 REGULATORY SCENARIO IN EUROPE	49
6.3 REGULATORY SCENARIO IN INDIA	50
6.4 REGULATORY SCENARIO IN CHINA	50
7 MARKET OVERVIEW	51

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.1 DRIVERS	53
7.1.1 INCREASE IN INFECTION AND ALLERGIC CASES	53
7.1.2 RISING PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA	53
7.1.3 EFFECTIVENESS OVER OTHER FORMS OF DRUG DELIVERY	54
7.1.4 IMPROVING PATIENT COMPLIANCE AND ACCEPTABILITY	55
7.2 RESTRAINTS	56
7.2.1 PRODUCT RECALLS	56
7.2.2 ADVERSE EFFECTS OF USING NASAL SPRAYS	57
7.3 OPPORTUNITIES	58
7.3.1 NEW RISING DEMAND FOR SELF-ADMINISTRATIVE DRUG DELIVERY	58
7.3.2 EXPANDING THERAPEUTIC APPLICATIONS FOR NASAL SPRAYS	58
7.3.3 STRATEGIC INITIATIVES TAKEN BY KEY MARKET PLAYERS	59
7.4 CHALLENGES	59
7.4.1 REGULATORY HURDLES	59
7.4.2 ADDICTION TO NASAL SPRAY	60
8 GLOBAL NASAL SPRAY MARKET, BY PRODUCT TYPE	61
8.1 OVERVIEW	62
8.2 DECONGESTION NASAL SPRAY	65
8.3 STEROID NASAL SPRAY	66
8.4 SALT WATER SOLUTION/SALINE NASAL SPRAY	67
8.5 OTHERS	68
9 GLOBAL NASAL SPRAY MARKET, BY CONTAINER DESIGN	69
9.1 OVERVIEW	70
9.2 PUMP BOTTLES	73
9.3 PRESSURIZED CANISTERS	74
10 GLOBAL NASAL SPRAY MARKET, BY DOSAGE FORM	75
10.1 OVERVIEW	76
10.2 MULTI DOSE	79
10.3 UNIT/SINGLE DOSE	80
10.4 BI DOSE	81
11 GLOBAL NASAL SPRAY MARKET, BY THERAPEUTIC CLASS	83
11.1 OVERVIEW	84
11.2 ANTIHISTAMINE	87
11.3 NASAL STEROIDS	88
11.4 MAST CELL INHIBITOR	89
11.5 ANTICHOLINERGIC	90
12 GLOBAL NASAL SPRAY MARKET, BY APPLICATION	91
12.1 OVERVIEW	92
12.2 NASAL CONGESTION	95
12.3 ALLERGIC AND NON-ALLERGIC RHINITIS	96
12.4 CENTRAL NERVOUS SYSTEM DISORDERS	97
12.5 VACCINATION	98
12.6 OTHERS	99
13 GLOBAL NASAL SPRAY MARKET, BY PRESCRIPTION/AVAILABILITY	100
13.1 OVERVIEW	101
13.2 PRESCRIBED	104
13.3 OVER THE COUNTER	105

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

14 GLOBAL NASAL SPRAY MARKET, BY END USER	107
14.1 OVERVIEW	108
14.2 HOME CARE SETTINGS	111
14.3 HOSPITALS	112
14.4 CLINICS	113
14.5 COMMUNITY HEALTH CARE	114
15 GLOBAL NASAL SPRAY MARKET, BY REGION	115
15.1 OVERVIEW	116
15.2 NORTH AMERICA	122
15.2.1 U.S.	129
15.2.2 CANADA	131
15.2.3 MEXICO	133
15.3 EUROPE	135
15.3.1 GERMANY	143
15.3.2 U.K.	145
15.3.3 FRANCE	147
15.3.4 ITALY	149
15.3.5 SPAIN	151
15.3.6 SWITZERLAND	153
15.3.7 NETHERLANDS	155
15.3.8 BELGIUM	157
15.3.9 RUSSIA	159
15.3.10 TURKEY	161
15.3.11 REST OF EUROPE	163
15.4 ASIA-PACIFIC	164
15.4.1 CHINA	172
15.4.2 JAPAN	174
15.4.3 INDIA	176
15.4.4 AUSTRALIA	178
15.4.5 SOUTH KOREA	180
15.4.6 MALAYSIA	182
15.4.7 THAILAND	184
15.4.8 SINGAPORE	186
15.4.9 INDONESIA	188
15.4.10 PHILIPPINES	190
15.4.11 REST OF ASIA-PACIFIC	192
15.5 SOUTH AMERICA	193
15.5.1 BRAZIL	200
15.5.2 ARGENTINA	202
15.5.3 REST OF SOUTH AMERICA	204
15.6 MIDDLE EAST AND AFRICA	205
15.6.1 SOUTH AFRICA	212
15.6.2 UAE	214
15.6.3 SAUDI ARABIA	216
15.6.4 REST OF MIDDLE EAST & AFRICA	218
16 GLOBAL NASAL SPRAY MARKET, COMPANY LANDSCAPE	219
16.1 COMPANY SHARE ANALYSIS: GLOBAL	219

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 220
- 16.3 COMPANY SHARE ANALYSIS: EUROPE 221
- 16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 222
- 17 SWOT ANALYSIS 223
- 18 COMPANY PROFILE 224
 - 18.1 GLAXOSMITHKLINE PLC. 224
 - 18.1.1 COMPANY SNAPSHOT 224
 - 18.1.2 REVENUE ANALYSIS 224
 - 18.1.3 COMPANY SHARE ANALYSIS 225
 - 18.1.4 PRODUCT PORTFOLIO 225
 - 18.1.5 RECENT DEVELOPMENTS 225
 - 18.2 PFIZER INC. 227
 - 18.2.1 COMPANY SNAPSHOT 227
 - 18.2.2 REVENUE ANALYSIS 227
 - 18.2.3 COMPANY SHARE ANALYSIS 228
 - 18.2.4 PRODUCT PORTFOLIO 228
 - 18.2.5 RECENT DEVELOPMENTS 228
 - 18.3 EMERGENT 230
 - 18.3.1 COMPANY SNAPSHOT 230
 - 18.3.2 REVENUE ANALYSIS 230
 - 18.3.3 COMPANY SHARE ANALYSIS 231
 - 18.3.4 PRODUCT PORTFOLIO 231
 - 18.3.5 RECENT DEVELOPMENT 231
 - 18.4 SANDOZ INTERNATIONAL GMBH (A PART OF NOVARTIS) 232
 - 18.4.1 COMPANY SNAPSHOT 232
 - 18.4.2 REVENUE ANALYSIS 232
 - 18.4.3 COMPANY SHARE ANALYSIS 233
 - 18.4.4 PRODUCT PORTFOLIO 233
 - 18.4.5 RECENT DEVELOPMENT 233
 - 18.5 CATALENT, INC. 234
 - 18.5.1 COMPANY SNAPSHOT 234
 - 18.5.2 REVENUE ANALYSIS 234
 - 18.5.3 COMPANY SHARE ANALYSIS 235
 - 18.5.4 PRODUCT PORTFOLIO 235
 - 18.5.5 RECENT DEVELOPMENTS 235
 - 18.6 AYTU HEALTH (A SUBSIDIARY OF AYTU BIOPHARMA, INC.) 237
 - 18.6.1 COMPANY SNAPSHOT 237
 - 18.6.2 REVENUE ANALYSIS 237
 - 18.6.3 PRODUCT PORTFOLIO 238
 - 18.6.4 RECENT DEVELOPMENTS 238
 - 18.7 AISHWARYA GROUP 239
 - 18.7.1 COMPANY SNAPSHOT 239
 - 18.7.2 PRODUCT PORTFOLIO 239
 - 18.7.3 RECENT DEVELOPMENTS 239
 - 18.8 ASSERTIO THERAPEUTICS, INC. 240
 - 18.8.1 COMPANY SNAPSHOT 240
 - 18.8.2 REVENUE ANALYSIS 240

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

18.8.3	PRODUCT PORTFOLIO	241
18.8.4	RECENT DEVELOPMENT	241
18.9	AURENA LABORATORIES.	242
18.9.1	COMPANY SNAPSHOT	242
18.9.2	PRODUCT PORTFOLIO	242
18.9.3	RECENT DEVELOPMENTS	242
18.10	BAYER AG	244
18.10.1	COMPANY SNAPSHOT	244
18.10.2	REVENUE ANALYSIS	244
18.10.3	COMPANY SHARE ANALYSIS	245
18.10.4	PRODUCT PORTFOLIO	245
18.10.5	RECENT DEVELOPMENTS	245
18.11	CIPLA INC.	247
18.11.1	COMPANY SNAPSHOT	247
18.11.2	REVENUE ANALYSIS	247
18.11.3	PRODUCT PORTFOLIO	248
18.11.4	RECENT DEVELOPMENT	248
18.12	J PHARMACEUTICALS.	249
18.12.1	COMPANY SNAPSHOT	249
18.12.2	PRODUCT PORTFOLIO	249
18.12.3	RECENT DEVELOPMENTS	249
18.13	LEEFORD HEALTHCARE LTD	250
18.13.1	COMPANY SNAPSHOT	250
18.13.2	PRODUCT PORTFOLIO	250
18.13.3	RECENT DEVELOPMENTS	250
18.14	ST. RENATUS.	251
18.14.1	COMPANY SNAPSHOT	251
18.14.2	PRODUCT PORTFOLIO	251
18.14.3	RECENT DEVELOPMENTS	251
18.15	TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD)	252
18.15.1	COMPANY SNAPSHOT	252
18.15.2	REVENUE ANALYSIS	252
18.15.3	PRODUCT PORTFOLIO	253
18.15.4	RECENT DEVELOPMENTS	253
18.16	ULTRATECH INDIA LIMITED	254
18.16.1	COMPANY SNAPSHOT	254
18.16.2	PRODUCT PORTFOLIO	254
18.16.3	RECENT DEVELOPMENTS	254
18.17	VIATRIS INC.	255
18.17.1	COMPANY SNAPSHOT	255
18.17.2	REVENUE ANALYSIS	255
18.17.3	COMPANY SHARE ANALYSIS	256
18.17.4	PRODUCT PORTFOLIO	256
18.17.5	RECENT DEVELOPMENT	256
19	QUESTIONNAIRE	257
20	RELATED REPORTS	261

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Nasal Spray Market - Industry Trends and Forecast to 2030

Market Report | 2023-03-01 | 261 pages | Data Bridge Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4800.00
	Corporate Users License	\$7000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-31"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com